The FDA has approved two new cardiac resynchronization therapy-pacemaker (CRT-P) systems manufactured by Medtronic, the company announced. Both the Consulta® and Syncra™ CRT-P systems include an ECG reporting system, which works with the company’s network data monitoring system to offer remote follow-up of heart-failure patients. In addition, the Consulta includes Medtronic’s fluid monitoring system and…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.